Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
GT Biopharma, Inc.
gtbiopharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
GT Biopharma received a 180-day extension from Nasdaq to regain compliance with minimum bid price requirements, pushing the deadline to November 16, 2026. This provides the company additional time to improve stock performance but signals ongoing listing risk.
Key Takeaways
Nasdaq granted an extended compliance period of 180 calendar days, extending the deadline to November 16, 2026, for compliance with Listing Rule 5550(a)(2)
The company's stock has fallen below Nasdaq's minimum bid price threshold, triggering the compliance requirement
2 more takeaways